Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Stoke Therapeutics (NASDAQ:STOK) had its price target upped by investment analysts at Needham & Company LLC from $35.00 to $40.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 17.79% from the stock’s current price.

A number of other analysts have also commented on STOK. Loop Capital set a $35.00 target price on Stoke Therapeutics in a research report on Monday, January 5th. Wedbush increased their price target on Stoke Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Monday, January 12th. Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a research note on Monday, December 29th. Canaccord Genuity Group boosted their price objective on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, Guggenheim started coverage on Stoke Therapeutics in a research report on Thursday, February 5th. They set a “buy” rating and a $60.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Stoke Therapeutics Trading Up 2.3%

NASDAQ:STOK opened at $33.96 on Tuesday. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $40.22. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of 50.69 and a beta of 1.07. The firm has a fifty day simple moving average of $32.74 and a two-hundred day simple moving average of $29.80.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.22). The company had revenue of $1.40 million for the quarter, compared to analyst estimates of $5.32 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. Equities analysts predict that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Arthur Tzianabos sold 4,355 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the completion of the sale, the insider directly owned 31,339 shares of the company’s stock, valued at approximately $1,253,560. The trade was a 12.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Adrian R. Krainer sold 33,243 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the sale, the director directly owned 283,302 shares of the company’s stock, valued at approximately $11,258,421.48. This trade represents a 10.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of STOK. Kestra Advisory Services LLC purchased a new position in Stoke Therapeutics during the 4th quarter worth $26,000. Harbour Investments Inc. raised its holdings in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC bought a new position in shares of Stoke Therapeutics during the third quarter valued at about $41,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after purchasing an additional 658 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.